["alzheimer's disease"]
['vx-745']

        Inclusion Criteria:

          -  Age 60 - 85 (inclusive)

          -  Willing and able to provide informed consent

          -  Clinical presentation consistent with MCI due to AD or of mild AD

               -  Gradual progressive decline in memory function over >6 months

               -  Amnestic presentation on neuropsychological testing with rapid forgetting (%
                  reduction 1.5 standard deviations below the mean)

               -  Clinical Dementia Rating (CDR) Sum of Box (SOB) score ≥0.5

               -  Mini-Mental State Examination (MMSE) range: 20 to 30

          -  Brain hypometabolism by 18F-2-fluoro-2-deoxyglucose (FDG)-PET

          -  Participants may be taking medications for AD, provided that the dose of these
             medications has been stable for >3 months.

        Exclusion Criteria:

          -  Evidence of neurodegenerative disease other than AD

          -  Inability for any reason to undergo MRI scans (e.g. pacemaker, vascular stent or stent
             graft). Patients who require sedation for screening procedures such as MRI may receive
             a short-acting sedative.

          -  Psychiatric disorder that would compromise ability to comply with study requirements

          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression
             over the past 2 years

          -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
             disorder or metabolic/endocrine disorders or other disease that would preclude
             treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy

          -  Recent (<90 days) changes to AD medications prescribed for cognitive reasons or with
             the potential to impact cognition

          -  Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.

          -  Participation in a study of an investigational drug less than 6 months or 5 half-lives
             of the investigational drug, whichever is longer, before enrollment in the study

          -  Male subjects with female partner of child-bearing potential who are unwilling or
             unable to adhere to contraception requirements

          -  Female subjects who have not reached menopause or have not had a hysterectomy or
             bilateral oophorectomy/salpingoophorectomy

          -  Positive urine or serum pregnancy test or plans desires to become pregnant during the
             course of the trial

          -  Donation of >500 mL of blood or blood products within 2 months

          -  History of alcohol and/or illicit drug abuse within 6 months.

          -  Infection with hepatitis A, B or C or HIV.

          -  Any factor deemed by the investigator to be likely to interfere with study conduction
      